M
Marc Cantillon
Researcher at Critical Path Institute
Publications - 8
Citations - 1315
Marc Cantillon is an academic researcher from Critical Path Institute. The author has contributed to research in topics: Frontotemporal lobar degeneration & Resilience (network). The author has an hindex of 8, co-authored 8 publications receiving 845 citations.
Papers
More filters
Journal ArticleDOI
Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance
Yaakov Stern,Eider M. Arenaza-Urquijo,David Bartrés-Faz,Sylvie Belleville,Marc Cantilon,Gaël Chételat,Michael Ewers,Nicolai Franzmeier,Gerd Kempermann,William S. Kremen,Ozioma C. Okonkwo,Nikolaos Scarmeas,Nikolaos Scarmeas,Anja Soldan,Chinedu T. Udeh-Momoh,Michael Valenzuela,Prashanthi Vemuri,Eero Vuoksimaa,Eider M. Arenaza Urquiljo,Marc Cantillon,Sean A. P. Clouston,Ainara Estanga,Brian T. Gold,Christian G. Habeck,Richard N. Jones,Renata Kochhann,W.S. Kremen,Yen Ying Lim,Pablo Martinez-Lage,Silvia Morbelli,Rik Ossenkoppele,Corinne Pettigrew,Allyson C. Rosen,Xiaowei Song,Anita C. van Loenhoud +34 more
TL;DR: The reserve, resilience, and protective factors professional interest area established a whitepaper workgroup to develop consensus definitions for cognitive reserve, brain reserve, and brain maintenance and evaluated measures that have been used to implement these concepts in research settings and developed guidelines for research that explores or utilizes these concepts.
Journal ArticleDOI
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease
Clifford R. Jack,Frederik Barkhof,Matt A. Bernstein,Marc Cantillon,Patricia E. Cole,Charles DeCarli,Bruno Dubois,Simon Duchesne,Nick C. Fox,Giovanni B. Frisoni,Harald Hampel,Derek L. G. Hill,Keith A. Johnson,Jean Franc¸ois Mangin,Philip Scheltens,Adam J. Schwarz,Reisa A. Sperling,Joyce Suhy,Paul M. Thompson,Michael W. Weiner,Michael W. Weiner,Norman L. Foster +21 more
TL;DR: The European Alzheimer's Disease Centers-Alzheimer's Disease Neuroimaging Initiative hippocampal harmonization effort as a reference standard is described in this paper, and a publicly available reference standard data set based on manual delineation of the hippocampus in an appropriate sample of subjects is established.
Journal Article
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease
Clifford R. Jack,Frederik Barkhof,Matt A. Bernstein,Marc Cantillon,Patricia E. Cole,Charles DeCarli,Bruno Dubois,Simon Duchesne,Nick C. Fox,Giovanni B. Frisoni,Harald Hampel,Derek L. G. Hill,Keith A. Johnson,Jean Franc¸ois Mangin,Philip Scheltens,Adam J. Schwarz,Reisa A. Sperling,Joyce Suhy,Paul M. Thompson,Michael W. Weiner,Michael W. Weiner,Norman L. Foster +21 more
TL;DR: Hippocampal volumetry is the most widely studied quantitative magnetic resonance imaging measure in Alzheimer's disease and thus represents the most rational target for an initial effort at standardization.
Journal ArticleDOI
Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease
Derek L. G. Hill,Adam J. Schwarz,Maria Isaac,Luca Pani,Spiros Vamvakas,Robert Hemmings,Maria C. Carrillo,Peng Yu,Jia Sun,Jia Sun,Laurel A. Beckett,Marina Boccardi,James B. Brewer,Martha Brumfield,Marc Cantillon,Patricia E. Cole,Nick C. Fox,Giovanni B. Frisoni,Clifford R. Jack,Thomas Kelleher,Feng Luo,Gerald Novak,Paul Maguire,Richard Meibach,Patricia Patterson,Lisa J. Bain,Cristina Sampaio,David Raunig,Holly Soares,Joyce Suhy,Huanli Wang,Robin Wolz,Diane Stephenson +32 more
TL;DR: Regulatory qualification of a biomarker for a defined context of use provides scientifically robust assurances to sponsors and regulators that accelerate appropriate adoption of biomarkers into drug development.
Journal ArticleDOI
Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development
Adam L. Boxer,Michael Gold,Edward D. Huey,Fen-Biao Gao,Edward A. Burton,Tiffany W. Chow,Aimee W. Kao,Blair R. Leavitt,Bruce T. Lamb,Megan Grether,David S. Knopman,Nigel J. Cairns,Ian R. A. Mackenzie,Laura L. Mitic,Erik D. Roberson,Daniel Van Kammen,Marc Cantillon,Kathleen R. Zahs,Stephen Salloway,John C. Morris,Gary Tong,Howard Feldman,Howard Fillit,Susan Dickinson,Zaven S. Khachaturian,Margaret Sutherland,Robert V. Farese,Bruce L. Miller,Jeffrey L. Cummings +28 more
TL;DR: Key findings are reported, including the rationale for FTD drug development; epidemiological, genetic, and neuropathological features of FTD; FTD animal models and how best to use them; and examples of successful drug development collaborations in other neurodegenerative diseases.